The Novel Pathogenic Mutation c.849dupT in BRCA2 Contributes to the Nonsense-Mediated mRNA Decay of BRCA2 in Familial Breast Cancer

In this study, we used next-generation sequencing methods to screen 300 individuals for BRCA1 and BRCA2. A novel mutation (c.849dupT) in BRCA2 was identified in a female patient and her unaffected brothers. This mutation leads to the truncation of BRCA2 functional domains. Moreover, BRCA2 mRNA expression levels in mutation carriers are significantly reduced compared to noncarriers. Immunofluorescence and western blot assays showed that this mutation resulted in reduced BRCA2 protein expression. Thus, we identified a novel mutation that damaged the function and expression of BRCA2 in a family with breast cancer history. The pedigree analysis suggested that this mutation is strongly associated with familial breast cancer. Genetic counsellors suggest that mutation carriers in this family undergo routine screening for breast cancer, as well as other malignancies, such as prostate and ovarian cancer. The effects of this BRCA2 mutation on drug resistance should be taken into consideration during treatment.

[1]  D. Jäger,et al.  Mutations in BRCA2 and taxane resistance in prostate cancer , 2017, Scientific Reports.

[2]  I. Papasotiriou,et al.  Current perspectives on CHEK2 mutations in breast cancer , 2017, Breast cancer.

[3]  B. Arun,et al.  BRCA mutation genetic testing implications in the United States. , 2017, Breast.

[4]  Jichun Yang,et al.  A novel loss-of-function heterozygous BRCA2 c.8946_8947delAG mutation found in a Chinese woman with family history of breast cancer , 2017, Journal of Cancer Research and Clinical Oncology.

[5]  A. Skol,et al.  The genetics of breast cancer risk in the post-genome era: thoughts on study design to move past BRCA and towards clinical relevance , 2016, Breast Cancer Research.

[6]  Xiaojia Wang,et al.  Novel germline mutations and unclassified variants of BRCA1 and BRCA2 genes in Chinese women with familial breast/ovarian cancer , 2016, BMC Cancer.

[7]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[8]  Serena Nik-Zainal,et al.  Mechanisms underlying mutational signatures in human cancers , 2014, Nature Reviews Genetics.

[9]  R. Eeles,et al.  Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Ferlay,et al.  An international comparison of male and female breast cancer incidence rates , 2013, International journal of cancer.

[11]  A. Venkitaraman,et al.  The Breast Cancer Susceptibility Gene BRCA2 Is Required for the Maintenance of Telomere Homeostasis* , 2011, The Journal of Biological Chemistry.

[12]  E. Swisher,et al.  Secondary mutations of BRCA1/2 and drug resistance , 2011, Cancer science.

[13]  P. Miron,et al.  PALB2 mutations in familial breast and pancreatic cancer , 2011, Familial Cancer.

[14]  D. Easton,et al.  Models of genetic susceptibility to breast cancer , 2006, Oncogene.

[15]  A. Venkitaraman,et al.  Stabilization of stalled DNA replication forks by the BRCA2 breast cancer susceptibility protein. , 2003, Genes & development.

[16]  Wen-Hwa Lee,et al.  BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. , 2002, Science.

[17]  Douglas F Easton,et al.  BRCA1 and BRCA2 mutations in a population-based study of male breast cancer , 2001, Breast Cancer Research.

[18]  P. Bork,et al.  Internal repeats in the BRCA2 protein sequence , 1996, Nature Genetics.

[19]  J. Rommens,et al.  BRCA2 germline mutations in male breast cancer cases and breast cancer families , 1996, Nature Genetics.

[20]  U. Patel,et al.  Screening for germline mutations of the p53 gene in familial breast cancer patients , 1995, European journal of clinical investigation.

[21]  A. Ouhtit,et al.  BRIP1, a potential candidate gene in development of non-BRCA1/2 breast cancer. , 2016, Frontiers in bioscience.